Obejective: To investigate the effects of ezetimibe and atorvastatin on the oxidative stress and blood lipid levels in patients with coronary heart disease and its clinical efficacy. Methods: 144 cases with coronary heart disease who were treated in our hospital from August 2013 to August 2016 were selected and randomly divided into the control group and the study group, with 72 cases in each group. The patients in the control group were treated with atorvastatin and nitroglycerin, while the patients in the study group were treated with atorvastatin and ezetimibe. Then the serum levels of peroxidase (MPO), propylene glycol (MDA), superoxide dismutase (SOD), total cholesterol (TC), glycerin three greases (TG), low density lipoprotein (LDL-C) and high density lipoprotein (HDL-C), heart functions and clinical curative effect between the two groups were observed and compared before and after the treatment. Results: The total clinical effective rate in the study group was 87.5%, which was higher than 76.4%in the control group, and the difference was statistically significant (P<0.05); After the treatment, the serum levels of MDA and MPO decreased in the two groups, while the SOD increased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the serum levels of MDA and MPO were lower in the study group, and the SOD was higher, and the differences were statistically significant (P<0.05); After treatment, the serum levels of HDL-C increased in the two groups, while the levels of LDL-C, TC and TG decreased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the serum levels of HDL-C was higher in the study group, and the levels of LDL-C, TC and TG were lower, and the differences were statistically significant (P<0.05); Compared with before treatment, the LVEDD and LVESD decreased in the two groups after the treatment, while the LVEF increased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the LVEDD and LVESD were lower in the study group, and the LVEF was higher, and the differences were statistically significant (P<0.05). Conclusions: Ezetimibe and atorvastatin have obvious clinical efficacy on the treatment of coronary heart disease, which can reduce the blood lipid levels of patients, and improve the oxidative stress and heart function, and it is worthy of clinical application. [ABSTRACT FROM AUTHOR]